Consensus on the Management of Inavolisib Side Effects. A Survey on Defined Side Effects, the Assumed Pathomechanism, Preventative and/or Therapeutic Measures Including the Integration of Additional Health Care Professionals - a Consensus Paper.

This consensus paper depicts prevention, identification, treatment, and the involvement of relevant medical specialists and other health care professionals in the management of defined side effects of the new selective oral PI3K inhibitor inavolisib. All topics were discussed and agreed upon between experts in oncology, gynecology, and diabetology from both clinical and private practice. In addition to a brief summary of the assumed pathomechanism of each selected side effect, the management of the defined adverse effects is described, based on respective severity and according to the summary of product characteristics (SmPC). These details are supplemented by the expertise and experience of the participating experts regarding possible preventative and supportive therapeutic measures, special precautions, and practical recommendations for daily clinical practice and patient management.